Module 18 2021

08/02/2021

Incorporation of drug into Transdermal delivery system (TDS)

• Incorporate drug into patch matrix • Slow release, sustained plasma levels at therapeutic level • Less frequent application (dose)

The Organisation for Professionals in Regulatory Affairs

23

Medicated TDS: What are the safety considerations?

• Target organ toxicity • Local toxicity • Degradant/impurity profile

The Organisation for Professionals in Regulatory Affairs

24

12